These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 19638462)

  • 1. A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors.
    Reid AH; Protheroe A; Attard G; Hayward N; Vidal L; Spicer J; Shaw HM; Bone EA; Carter J; Hooftman L; Harris A; De Bono JS
    Clin Cancer Res; 2009 Aug; 15(15):4978-85. PubMed ID: 19638462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours.
    van Herpen CM; Eskens FA; de Jonge M; Desar I; Hooftman L; Bone EA; Timmer-Bonte JN; Verweij J
    Br J Cancer; 2010 Oct; 103(9):1362-8. PubMed ID: 20877350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.
    Löwenberg B; Morgan G; Ossenkoppele GJ; Burnett AK; Zachée P; Dührsen U; Dierickx D; Müller-Tidow C; Sonneveld P; Krug U; Bone E; Flores N; Richardson AF; Hooftman L; Jenkins C; Zweegman S; Davies F
    J Clin Oncol; 2010 Oct; 28(28):4333-8. PubMed ID: 20733120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.
    de Bono JS; Kristeleit R; Tolcher A; Fong P; Pacey S; Karavasilis V; Mita M; Shaw H; Workman P; Kaye S; Rowinsky EK; Aherne W; Atadja P; Scott JW; Patnaik A
    Clin Cancer Res; 2008 Oct; 14(20):6663-73. PubMed ID: 18927309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Zujewski J; Horak ID; Bol CJ; Woestenborghs R; Bowden C; End DW; Piotrovsky VK; Chiao J; Belly RT; Todd A; Kopp WC; Kohler DR; Chow C; Noone M; Hakim FT; Larkin G; Gress RE; Nussenblatt RB; Kremer AB; Cowan KH
    J Clin Oncol; 2000 Feb; 18(4):927-41. PubMed ID: 10673536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.
    Wojtowicz-Praga S; Torri J; Johnson M; Steen V; Marshall J; Ness E; Dickson R; Sale M; Rasmussen HS; Chiodo TA; Hawkins MJ
    J Clin Oncol; 1998 Jun; 16(6):2150-6. PubMed ID: 9626215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
    Kelly WK; O'Connor OA; Krug LM; Chiao JH; Heaney M; Curley T; MacGregore-Cortelli B; Tong W; Secrist JP; Schwartz L; Richardson S; Chu E; Olgac S; Marks PA; Scher H; Richon VM
    J Clin Oncol; 2005 Jun; 23(17):3923-31. PubMed ID: 15897550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
    Ramalingam SS; Parise RA; Ramanathan RK; Lagattuta TF; Musguire LA; Stoller RG; Potter DM; Argiris AE; Zwiebel JA; Egorin MJ; Belani CP
    Clin Cancer Res; 2007 Jun; 13(12):3605-10. PubMed ID: 17510206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
    Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Goffin JR; Anderson IC; Supko JG; Eder JP; Shapiro GI; Lynch TJ; Shipp M; Johnson BE; Skarin AT
    Clin Cancer Res; 2005 May; 11(9):3417-24. PubMed ID: 15867243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells.
    Krige D; Needham LA; Bawden LJ; Flores N; Farmer H; Miles LE; Stone E; Callaghan J; Chandler S; Clark VL; Kirwin-Jones P; Legris V; Owen J; Patel T; Wood S; Box G; Laber D; Odedra R; Wright A; Wood LM; Eccles SA; Bone EA; Ayscough A; Drummond AH
    Cancer Res; 2008 Aug; 68(16):6669-79. PubMed ID: 18701491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
    Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
    Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.
    Propper DJ; McDonald AC; Man A; Thavasu P; Balkwill F; Braybrooke JP; Caponigro F; Graf P; Dutreix C; Blackie R; Kaye SB; Ganesan TS; Talbot DC; Harris AL; Twelves C
    J Clin Oncol; 2001 Mar; 19(5):1485-92. PubMed ID: 11230495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
    Ryan QC; Headlee D; Acharya M; Sparreboom A; Trepel JB; Ye J; Figg WD; Hwang K; Chung EJ; Murgo A; Melillo G; Elsayed Y; Monga M; Kalnitskiy M; Zwiebel J; Sausville EA
    J Clin Oncol; 2005 Jun; 23(17):3912-22. PubMed ID: 15851766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
    Giles F; Fischer T; Cortes J; Garcia-Manero G; Beck J; Ravandi F; Masson E; Rae P; Laird G; Sharma S; Kantarjian H; Dugan M; Albitar M; Bhalla K
    Clin Cancer Res; 2006 Aug; 12(15):4628-35. PubMed ID: 16899611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.
    Steele NL; Plumb JA; Vidal L; Tjørnelund J; Knoblauch P; Rasmussen A; Ooi CE; Buhl-Jensen P; Brown R; Evans TR; DeBono JS
    Clin Cancer Res; 2008 Feb; 14(3):804-10. PubMed ID: 18245542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.